Related Experiment Video
Updated: Jul 18, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Telavancin: a new lipoglycopeptide with multiple mechanisms of action
1Duke University Medical Center, Duke Clinical Research Institute, Division of Infectious Diseases, 2400 Pratt Street, Rm 7543, Durham, NC 27710, USA. kanaf001@mc.duke.edu
Abstract:
Antimicrobial resistance among Gram-positive organisms continues to increase and has reached epidemic proportions in numerous countries. Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action that involves the inhibition of cell-wall synthesis and disruption of bacterial cell-membrane barrier functions. Telavancin exhibits a rapid bactericidal activity against Staphylococcus aureus. It is also active against coagulase-negative staphylococci, enterococci, streptococci and various anaerobic Gram-positive organisms. Telavancin has a prolonged postantibiotic effect and distributes well into cutaneous and pulmonary tissues. Furthermore, it has a low potential for development of resistance and is well tolerated. The overall incidence of adverse events in patients receiving telavancin was similar to that observed with standard therapy and recent data from preliminary clinical trials have demonstrated similar efficacy to standard therapy in the treatment of complicated skin and skin-structure infections. Therefore, telavancin is a promising new antimicrobial agent for the treatment of infections caused by resistant Gram-positive pathogens.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Mechanism of Antibiotic Resistance in MRSA
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial DNA Synthesis
